IO/Targeted Combos Poised to Enter Metastatic Urothelial Carcinoma Paradigm
Published: Thursday, Mar 26, 2020
Daniel P. Petrylak, MD
The rapid influx of immunotherapy and targeted therapy approvals in metastatic urothelial carcinoma has led research efforts to pivot toward potentially enhancing response rates with combination regimens, said Daniel P. Petrylak, MD.
... to read the full story